The global meningitis diagnostic testing market was valued over US$
105.5 Mn in 2016 and is projected to register cumulative annual
growth rate (CAGR) of over 3.0% from 2017 to 2025, according to a new
report published by Transparency Market Research (TMR) titled
“Meningitis Diagnostic Testing Market – Global Industry Analysis,
Size, Share, Growth, Trends, and Forecast, 2017–2025”. The report
suggests that rising demand for innovative technologies and adoption
of rapid testing methods such as point of care testing is spurring
the growth of meningitis diagnostic testing in coming years (2017 to
2025). The North America and Asia Pacific are projected to dominate
the global meningitis diagnostic testing market in the coming years
owing to due availability of rapid diagnostic tests, routine
vaccination programs to prevent meningitis, and increased patient
awareness. Middle East & Africa is projected to account
significant market share by 2025. This is attributed to large
meningitis patient base in Sub-Saharan Africa (also known as
Meningitis Belt). Growing adoption of technologically advanced
products manufactured by key manufacturers like IMMY, BioFire
Diagnostics, etc. is likely to drive the rapid diagnostic testing
across globe. The Asia Pacific meningitis diagnostic testing market
is expected to witness highest CAGR of over 4.0% from 2017 to 2025.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1973
New, innovative technologies such PCR and next-generation sequencing
are available in the market, providing a less expensive way for the
diagnosis, prognosis, and therapy selection in patients during their
treatment. This helps physicians frame appropriate therapeutic
systems for patients suffering from the infectious disease. Rising
demand for point-of-care services is anticipated to drive the
meningitis diagnostic testing market during the forecast period.
Point-of-care services provide more accurate results in less time as
compared to traditional methods. Culture diagnostics has been less
adopted separately, due to test limitations, lower specificity,
higher time required, and the recent trend of slower adoption of
culture tests compared to other reliable tests available.
The report offers detailed segmentation of global meningitis
diagnostic testing market based on product, and end-user. Among the
product segment, PCR Assay segment is poised to account for leading
share of the global market during the forecast period from 2017 to
2025. Factors attributed to the higher share of the PCR assay segment
in the global market include ability of PCR to diagnose the disease
within a short time period drives the PCR assay segment. Development
and launch of new PCR assays with increased automation (such as
BioFire FilmArray Multiplex PCR system) for the diagnosis of
meningitis have boosted the segment. Also, PCR assays are estimated
become more commonplace for meningitis diagnosis in the next five to
10 years. Globally, point-of-care lateral flow assay is an ideal test
for meningitis diagnosis in settings with limited resources. This
leads to wide adoption of these assays. This, in turn, drives the
lateral flow assay segment.
Among end-user, hospitals segment is projected to hold dominant share
of global meningitis diagnostic testing market during the forecast
period and is likely to expand at CAGR more than 4.0% from 2017 to
2025. Major reason responsible for the dominance of this segment such
as Meningitis is a fatal disease that requires immediate care.
Therefore, increase in number of hospitals visit and rise in
prevalence of meningitis is projected to boost the hospitals segment
during forecast period. Diagnostic centres segment is projected to
hold substantial share of global meningitis diagnostic testing market
during the forecast period. Diagnostic centers are specially meant
only disease detection. They are well equipped with sophisticated
instruments, hence people in developing and under developed countries
prefer diagnostics centers.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1973
In terms of value, North America is likely to continue its dominance
in the global meningitis diagnostic testing market throughout the
forecast period, owing to early adoption of technologies, huge
patient pool of viral meningitis and significant average selling
prices of testing kits. Asia Pacific is projected to be the most
attractive market for meningitis diagnostics testing, with highest
attractiveness index. The market in the region is expected to expand
at a high CAGR of over 4.0% during the forecast period due to
presence of vast population base especially in China and India.
Increase in prevalence of chronic diseases such as HIV &
tuberculosis and surge in demand for rapid and automated diagnostics
have accelerated the growth of meningitis diagnostic testing market
in Asia Pacific region. The Incidence rate of meningitis is highest
in Middle East & Africa however, lack of laboratory
infrastructure, low disposable income, low penetration of advance
diagnostic tests and poor patient awareness hinders the total share
of the market. According to CDC, about 60% of total meningitis
population is present in Middle East & Africa, specifically
Sub-Saharan Africa (also known as Meningitis Belt).
The report also provide profiles of leading players operating in
global meningitis diagnostic testing market. Thermo Fisher
Scientific, Inc., BioFire Diagnostics, Fast Track Diagnostics Ltd.
(FTD) – Siemens Healthineers, Bio-Rad Laboratories, Inc., IMMY are
major players operating in the market, offering products with
proprietary technologies, such as BioFire offers proprietary products
(PCR assay kits) such as FilmArray Meningitis/Encephalitis panels.
Several key companies have recently introduced analytical instruments
that can carry out rapid analysis in near-patient settings. IMMY (a
diagnostic company based in the U.S.) CrAg LFA (Cryptococcal Antigen
Lateral Flow Assay) is an immunochromatographic dipstick assay for
the qualitative and semi-quantitative detection of cryptococcal
antigens. This lateral flow assay has revolutionized cryptococcal
antigen testing, by delivering analytical sensitivity that is about
200x more compared to other commercial assays. Other prominent
players in the global meningitis diagnostic testing market include
Nanosphere (Luminex Corporation), Seegene Inc., Qnostics,
ELITechGroup, and Abbott Laboratories.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment